Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity Lands $7.5M in Debt Financing

NEW YORK (GenomeWeb) – DxTerity Diagnostics announced on Tuesday that it has arranged to receive up to $7.5 million in term debt financing from SWK Funding, a subsidiary of SWK Holdings.

The firm said it will use the proceeds toward the commercialization of its DxDirect genomics testing platform and DxCollect MicroCollection Device (MCD).

The firm's proprietary chemistry, DxDirect, enables multiplexed genomic testing directly from the patient sample. The DxCollect MCD allows for the stabilization and transport of blood RNA collected from a finger or heel prick.

"This funding allows DxTerity to aggressively pursue the commercialization of its technology, including [the] expansion of DxDirect to next-generation sequencing systems, and [the use of] DxCollect MCD to power direct-to-patient clinical studies for accelerated validation of molecular diagnostic assays," DxTerity CEO Bob Terbrueggen said in a statement.

In February, a partnership between DxTerity and Duke University received $10.4 million from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority to continue developing a genetic test for radiation exposure.



The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.